Advanced Renal Cell Carcinoma: Importance of First-Line Therapy Selection and Treatment Prioritization

In this segment, the discussion focuses on the critical importance of first-line treatment selection in advanced renal cell carcinoma, particularly in the context of real-world data showing that many patients do not receive subsequent lines of therapy. Dr. Elizabeth Plimack emphasizes that the first-line setting represents a “precious” opportunity to deliver the most effective therapy, as clinicians cannot assume patients will reach later lines. She highlights that current evidence supports the use of combination approaches over less effective strategies, reinforcing the need to prioritize treatments with proven efficacy and potential for durable disease control. Dr. Brian Rini echoes this perspective, noting that patients often prefer receiving the most effective therapy upfront rather than reserving options for later. The discussion also touches on the cautious integration of emerging therapies, balancing innovation with the need to ensure patients receive established, effective treatments in the first-line setting of advanced renal cell carcinoma.